This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Thadepalli, H. Articles by Gollapudi, S. Search for Related Content PubMed PubMed Citation Articles by Thadepalli, H. Articles by Gollapudi, S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, 09 1997, 1933-1936, Vol 41, No. 9
Copyright © 1997 by the American Society for Microbiology. All rights reserved.

Efficacy of trovafloxacin for treatment of experimental Bacteroides infection in young and senescent mice

H Thadepalli, SK Chuah, U Reddy, N Hanna, R Clark, RJ Polzer and S Gollapudi
Division of Geriatrics and Gerontology, Charles R. Drew University of Medicine and Science, Los Angeles, California 90059, USA.

We investigated the efficacy of trovafloxacin, a new quinolone, in comparison with that of clindamycin in the treatment of intra-abdominal abscesses caused by Bacteroides fragilis in young and senescent mice. The development of abscess formation, the number of viable organisms, and antibiotic concentrations were measured, and the values for young and old mice were compared. Trovafloxacin was well distributed to the tissues in both young and old animals. Although the pharmacokinetics and concentrations of trovafloxacin in serum were similar between young and old mice, the levels in tissue were higher in senescent mice than in young mice. Trovafloxacin therapy sterilized abscesses in 94% of young mice and in 73% of old mice, but this difference was not significant. This therapeutic response to trovafloxacin was similar to that seen with clindamycin. These results suggest that aging may not have any adverse effect on the therapeutic outcome for intra-abdominal abscesses caused by B. fragilis.

This article has been cited by other articles:

• Noel, A. R., Bowker, K. E., MacGowan, A. P. (2005). Pharmacodynamics of Moxifloxacin against Anaerobes Studied in an In Vitro Pharmacokinetic Model. Antimicrob. Agents Chemother. 49: 4234-4239 [Abstract] [Full Text]  
• Weiss, T., Shalit, I., Blau, H., Werber, S., Halperin, D., Levitov, A., Fabian, I. (2004). Anti-Inflammatory Effects of Moxifloxacin on Activated Human Monocytic Cells: Inhibition of NF-{kappa}B and Mitogen-Activated Protein Kinase Activation and of Synthesis of Proinflammatory Cytokines. Antimicrob. Agents Chemother. 48: 1974-1982 [Abstract] [Full Text]  
• Golan, Y., McDermott, L. A., Jacobus, N. V., Goldstein, E. J. C., Finegold, S., Harrell, L. J., Hecht, D. W., Jenkins, S. G., Pierson, C., Venezia, R., Rihs, J., Iannini, P., Gorbach, S. L., Snydman, D. R. (2003). Emergence of fluoroquinolone resistance among Bacteroides species. J Antimicrob Chemother 52: 208-213 [Abstract] [Full Text]  
• Stearne, L. E. T., Gyssens, I. C., Goessens, W. H. F., Mouton, J. W., Oyen, W. J. G., van der Meer, J. W. M., Verbrugh, H. A. (2001). In Vivo Efficacy of Trovafloxacin against Bacteroides fragilis in Mixed Infection with either Escherichia coli or a Vancomycin-Resistant Strain of Enterococcus faecium in an Established-Abscess Murine Model. Antimicrob. Agents Chemother. 45: 1394-1401 [Abstract] [Full Text]  
• Thadepalli, H., Reddy, U., Chuah, S. K., Hanna, N., Rana, G., Gollapudi, S. (2000). Evaluation of trovafloxacin in the treatment of Klebsiella pneumoniae lung infection in tumour-bearing mice. J Antimicrob Chemother 45: 69-75 [Abstract] [Full Text]